GAR-936: Tetracycline Antibiotic

Drugs of the Future

Volumn 26, Issue 9, 2001, Pages 851-858

  Hunter, Pamela A ^a   Castaner J ^b  

^a Burnthouse   (United Kingdom)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0242553749     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.09.634733     Document Type: Article

References (39)

1. Sum, P.-E., Lee, V.E., Testa, R.T., Hlavka, J.J., Ellestad, G.A., Bloom, J.D., Gluzman, Y., Tally, F.P. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994, 37: 184-8.
2. Sum, P.E., Petersen, P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999, 9: 1459-62.
3. Sum, P.-E., Lee, V.J. (American Cyanamid Co.). Method of producing 7-(substd.)-9-[(substd. glycy/)amidol]-6-demethyl-6-deoxytetracyclines. EP 0582790, US 5284963.
4. Petersen, P.J., Jacobus, N.V., Weiss, W.J., Sum, P.E., Testa, R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43: 738-44.
5. Boucher, H.W., Wennersten, C.B., Eliopoulos, G.M. In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob Agents Chemother 2000, 44: 2225-9.
6. Patel, R., Rouse, M., Piper, K., Steckelberg, J. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000, 38: 177-9.
7. Hoellman, D.B., Pankuch, G.A., Jacobs, M.R., Appelbaum, P.C. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000, 44: 1085-8.
8. Gales, A.C., Jones, R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000, 36: 19-36.
9. Edlund, C., Nord, C. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6: 159-163.
10. Goldstein, E., Citron, D., Merriam, C., Warren, Y., Tyrrell, K. Comparative In vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000, 44: 2747-51.
11. Roblin, P.M., Hammerschlag, M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000, 16: 61-3.
12. Kenny, G.E., Cartwright, F.D. The susceptibilities of human mycoplasmas to a new glycylcycline, GAR-936. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F412.
13. Projan, S. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20(9, Part 2, Supp. S): 219S-23S.
14. Mikels, S.M., Lenoy, E., Allen, W., Compton, S., Weiss, W.J. Therapeutic efficacy of GAR-936, a novel glycylcycline, in murine infections. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F-135.
15. Mikels, S.M., Brown, A.S., Breden, L., Compton, S., Mitelman, S., Petersen, P.J., Weiss, W.J. In vivo activities of GAR-936 (GAR), gentamicin (GEN), piperacillin (PIP) alone and in combination in a murine model of Pseudomonas pneumonia. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F414.
16. van Ogtrop, M.L., Andes, D., Stamstad, T.J., Conklin, B., Weiss, W.J., Craig, W.A., Vesga, O. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000, 44: 943-9.
17. Murphy, T., Deitz, J., Petersen, P., Mikels, S., Weiss, W. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000, 44: 3022-7.
18. Lefort, A., Lafaurie, M., Saleh-Mghir, A., Garry, L., Peker, M.C., Le Guludec, D., Carbon, C., Fantin, B. Activity and diffusion of GAR-936 in experimental enterococcal endocarditis. 39th Intersci Coni Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F415.
19. Fang, G.D., Weiss, W.J., Scheld, W.M. Comparative efficacy of GAR-936 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst B-868.
20. Tombs, N.L. Tissue distribution of GAR-936, a broad spectrum antibiotic in rats. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F413.
21. Muralidharan, G., Gesty, J., Mayer, P., Paty, I., Micalizzi, M., Speth, J., Wester, B., Mojaverian, P. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F416.
22. Muralidharan, G., Mojaverian, P., Micalizzi, M., Speth, J., Tse, S., Stroshane, R., Getsy, J., Mayer, P. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst A-502.
23. Research and Development Product Pipeline. Wyeth Web Site January 23, 2001.
24. Tuckrnan, M., Projan, S.J. Characterization of tetA(B) resistant mutants. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst C-97.
25. Tuckman, M., Petersen, P.J., Projan, S.J. Mutations in the interdomain region of tetA(A) lead to glycylcycline-resistance in Salmonella isolates. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst C-98.
26. Petersen, P.J., Weiss, W.J., Labthavikul, P., Bradford, P.A. The post-antibiotic effect and time-kill kinetics of the glycylcyclines, GAR-936 (TBG-MINO) and PAM-MINO. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F-132.
27. Weiss, W.J., Murphy, T.M., Mikels, S.M., Clegg, J. GAR-936, a novel glycylcycline, in the treatment of experimental endocarditis. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F-136.
28. Boucher, H.W., Wennersten, C.B., Moellering, R.C., Eliopoulos, G.M. In vitro activity of GAR-936 against Gram-positive bacteria. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F406.
29. Jones, R.N., Gales, A.C., Deshpande, L.M., Johnson, D.M., Biedenbach, D.J. Antimicrobial activity of the novel glycylcycline GAP-936, tested against over 1000 recent clinical isolates including multiresistant Gram-positive cocci. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F407.
30. Mahalinggam, E., Trepeski, L., Pong-Porter, S., De Azavedo, J., Low, D.E., Kreiswirtn, B.N. In vitro activity of new glycylcycline, GAR 936 against methillicin-resistant and -susceptible Staphylococcus aureus isolated in North America. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F408.
31. Hoellman, D.B., Jacobs, M.R., Appelbaum, P.C. Antipneumococcal activity of GAR 936, a new glycylcycline, by agar dilution MIC. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F409.
32. Pankuch, G.A., Jacobs, M.R., Appelbaum, P.C. Antipneumoccocal activity of GAR 936, a new glycylcycline, compared with seven compounds by broth dilution and time-kill. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F410.
33. Hedberg, M., Nord, C.E. In vitro activity of anaerobic bacteria to GAR-936, a new glycylcycline. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst F411.
34. Petersen, P.J., Rittenhouse, J.L., Sum, P.E., Bradford, P.A. Effect of in vitro test methodologies on the activity of the glycylcyclines against Streptococcus pneumoniae. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst D-333.
35. Citron, D.M., Goldstein, E.J.C. Comparative in vitro activity of GAR-936, a novel glycylglycine, against 422 strains of unususal aerobic and anaerobic bacteria isolated from infected bite wounds. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst E-524.
36. Labthavikul, P., Bradford, P.A. In vitro susceptibility of adherent (biofilm) S. epidermidis clinical isolates to GAR-936 (GAR), minocycline (MINO) and vancomycin (VAN). 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst E-525.
37. Piper, K.E., Rouse, M.S., Wilson, W.R., Steckelberg, J.M., Patel, R. In vitro activity of GAR-936 against vancomycin resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant pneumococci. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst E-526.
38. Mercier, R.C., Kennedy, C., Meadows, C. Activities of GAR-936 alone and in combination versus multi-drug resistant Staphylococcus aureus and Enterococcus faecium. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst E-532.
39. Lefort, A., Massias, L., Saleh-Mghir, A., Lafaurie, M., Garry, L., Carbon, C., Fantin, B. Pharmacodynamics of GAR 936 (GAR) in experimental endocarditis due to VanA-type Enterococcus faecium. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst A-2256.